Browsing by Author "Barker, Frederick"

Now showing items 1-11 of 11

    • Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2 

      Plotkin, Scott Randall; Merker, Vanessa; Halpin, Chris; Jennings, Dominique; McKenna, Michael John; Harris, Gordon J.; Barker, Frederick George (Ovid Technologies (Wolters Kluwer Health), 2012)
      Objective: Early studies suggest that bevacizumab treatment can result in tumor shrinkage and hearing improvement for some patients with neurofibromatosis type 2 (NF2). The aim of this study was to report extended follow-up ...

    • Bevacizumab Treatment for Meningiomas in NF2: A Retrospective Analysis of 15 Patients 

      Nunes, Fabio; Merker, Vanessa L.; Jennings, Dominique; Caruso, Paul Albert; di Tomaso, Emmanuelle; Muzikansky, Alona; Barker, Frederick George; Stemmer-Rachamimov, Anat; Plotkin, Scott Randall (Public Library of Science (PLoS), 2013)
      Bevacizumab treatment can result in tumor shrinkage of progressive vestibular schwannomas in some neurofibromatosis 2 (NF2) patients but its effect on meningiomas has not been defined. To determine the clinical activity ...

    • Erlotinib for Progressive Vestibular Schwannoma in Neurofibromatosis 2 Patients 

      Plotkin, Scott Randall; Halpin, Chris; McKenna, Michael; Loeffler, Jay Steven; Batchelor, Tracy Todd; Barker, Frederick George (Ovid Technologies (Wolters Kluwer Health), 2010)
      In vitro treatment of Nf2-deficient cells with epidermal growth factor receptor (EGFR) inhibitors can inhibit cellular proliferation. We retrospectively assessed the effect of erlotinib (150 mg daily) on eleven consecutive ...

    • Hearing and facial function outcomes for neurofibromatosis 2 clinical trials 

      Plotkin, Scott Randall; Ardern-Holmes, S. L.; Barker, Frederick George; Blakeley, Jaishri O.; Evans, D. G.; Ferner, R. E.; Hadlock, Theresa A; Halpin, C. (Ovid Technologies (Wolters Kluwer Health), 2013)
      Objectives: Vestibular schwannomas are the hallmark of neurofibromatosis 2 (NF2), occurring in >95% of patients. These tumors develop on the vestibulocochlear nerve and are associated with significant morbidity due to ...

    • Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2 

      Plotkin, Scott Randall; Stemmer-Rachamimov, Anat; Barker, Frederick George; Halpin, Chris; Padera, Timothy P.; Tyrrell, Alex; Sorensen, A; Jain, Rakesh K.; di Tomaso, Emmanuelle (New England Journal of Medicine (NEJM/MMS), 2009)
      Background Profound hearing loss is a serious complication of neurofibromatosis type 2, a genetic condition associated with bilateral vestibular schwannomas, benign tumors that arise from the eighth cranial nerve. There ...

    • Natural History of Vestibular Schwannoma Growth and Hearing Decline in Newly Diagnosed Neurofibromatosis Type 2 Patients 

      Plotkin, Scott Randall; Merker, Vanessa; Muzikansky, Alona; Barker, Frederick George; Slattery, William (Ovid Technologies (Wolters Kluwer Health), 2014)
      Objective: To determine the rate of growth in vestibular schwannomas and the rate of hearing decline in neurofibromatosis type 2 (NF2) patients not undergoing active treatment Study Design: Prospective study. Setting: ...

    • Pregnancy complications in women with rare tumor suppressor syndromes affecting central and peripheral nervous system 

      Terry, Anna R.; Merker, Vanessa; Barker, Frederick George; Leffert, Lisa Rae; Bateman, Brian Thomas; Souter, Irene C.; Plotkin, Scott Randall (Elsevier BV, 2015)
      Neurofibromatosis type 2 (NF2), tuberous sclerosis (TS), and von Hippel-Lindau disease (VHL) are tumor suppressor syndromes characterized by multiple benign tumors of the peripheral and central nervous system.1 These tumors ...

    • Rapid Intraoperative Molecular Characterization of Glioma 

      Shankar, Ganesh Mani; Francis, Joshua M.; Rinne, Mikael Lee; Ramkissoon, Shakti; Huang, Franklin W; Venteicher, Andrew S; Akama-Garren, Elliot H.; Kang, Yun Jee; Lelic, Nina; Kim, James C.; Brown, Loreal E.; Charbonneau, Sarah K; Golby, Alexandra Jacqueline; Sekhar Pedamallu, Chandra; Hoang, Mai P; Sullivan, Ryan Joseph; Cherniack, Andrew D.; Garraway, Levi Alexander; Stemmer-Rachamimov, Anat; Reardon, David Allen; Wen, Patrick Yung Chih; Brastianos, Priscilla Kalliope; Curry, William Thomas; Barker, Frederick George; Hahn, William Chun; Nahed, Brian Vala; Ligon, Keith Lloyd; Louis, David N.; Cahill, Daniel P.; Meyerson, Matthew Langer (American Medical Association (AMA), 2015)
      IMPORTANCE: Conclusive intraoperative pathologic confirmation of diffuse infiltrative glioma guides the decision to pursue definitive neurosurgical resection. Establishing the intraoperative diagnosis by histologic analysis ...

    • Recommendations for imaging tumor response in neurofibromatosis clinical trials 

      Dombi, E.; Ardern-Holmes, S. L.; Babovic-Vuksanovic, D.; Barker, Frederick George; Connor, S.; Evans, D. G.; Fisher, Marc; Goutagny, S.; Harris, G. J.; Jaramillo, D.; Karajannis, M. A.; Korf, B. R.; Mautner, V.; Plotkin, Scott Randall; Poussaint, Tina Young; Robertson, Kent; Shih, C.-S.; Widemann, B. C.; undefined, undefined (Ovid Technologies (Wolters Kluwer Health), 2013)
      Objective: Neurofibromatosis (NF)-related benign tumors such as plexiform neurofibromas (PN) and vestibular schwannomas (VS) can cause substantial morbidity. Clinical trials directed at these tumors have become available. ...

    • Sporadic hemangioblastomas are characterized by cryptic VHL inactivation 

      Shankar, Ganesh Mani; Taylor-Weiner, Amaro; Lelic, Nina; Jones, Robert T; Kim, James C; Francis, Joshua M; Abedalthagafi, Malak S; Borges, Lawrence Francis; Coumans, Jean-Valery C E; Curry, William Thomas; Nahed, Brian Vala; Shin, John H; Paek, Sun Ha; Park, Sung-Hye; Stewart, Chip; Lawrence, Michael S; Cibulskis, Kristian; Thorner, Aaron R; Van Hummelen, Paul; Stemmer-Rachamimov, Anat; Batchelor, Tracy Todd; Carter, Scott Lambert; Hoang, Mai P; Santagata, Sandro; Louis, David N.; Barker, Frederick George; Meyerson, Matthew Langer; Getz, Gad A; Brastianos, Priscilla Kalliope; Cahill, Daniel P. (Springer Nature, 2014)
      Hemangioblastomas consist of 10-20% neoplastic “stromal” cells within a vascular tumor cell mass of reactive pericytes, endothelium and lymphocytes. Familial cases of central nervous system hemangioblastoma uniformly result ...

    • Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma 

      Plotkin, Scott Randall; Halpin, Chris; Blakeley, Jaishri O.; Slattery, William H.; Welling, Duane Bradley; Chang, Susan M.; Loeffler, Jay Steven; Harris, Gordon J.; Sorensen, A; McKenna, Michael John; Barker, Frederick George (Springer Nature, 2009)
      Neurofibromatosis type 2 (NF2) is a tumor suppressor gene syndrome characterized by multiple schwannomas, especially vestibular schwannomas (VS), and meningiomas. Anticancer drug trials are now being explored, but there ...